PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
N Engl J Med. Author manuscript; available in PMC 2010 October 26.
Published in final edited form as:
PMCID: PMC2964068
NIHMSID: NIHMS242419

ISOHEMAGGLUTININS OF GRAFT ORIGIN AFTER ABO-UNMATCHED LIVER TRANSPLANTATION

Glenn Ramsey, M.D., Jacob Nusbacher, M.D., Thomas E. Starzl, M.D., Ph.D., and Gwenn D. Lindsay, B.A.

The increasing success of liver transplantation in recent years has provided an experimental model to study and document the hepatic synthesis of many plasma proteins.15 The normal hepatobiliary tract has not been regarded as a major source of antibody,6,7 aside from the enteric IgA secreted from plasma into the biliary tree.8 Liver transplantation affords the opportunity to study the production of antibody to red cells. Recipient ABO incompatibility to the donor (a mismatched transplant, e.g., a group A liver transplanted into a group B recipient), although not absolutely contraindicated in liver transplantation, is avoided when possible. However, ABO-unmatched transplants (defined as a group O liver transplanted into a non-group O recipient or a group A or B liver to an AB recipient) are used frequently. We report the short-term occurrence of anti-recipient ABO antibody after eight unmatched transplants. In five cases there was evidence of hemolysis. No such antibodies have been seen in over 180 ABO-matched transplants at our center. These antibodies were most probably produced by donor lymphocytes transplanted in or with the livers.

METHODS

Serologic studies were performed according to standard methods.9 Serum isohemagglutinins were tested without intubation, after 37°C incubation for 30 minutes, and with broad-spectrum antiglobulin reagents.

Six patients with ABO-unmatched liver transplants and confirmed anti-recipient antibody production were studied prospectively. Blood samples were drawn at least weekly for direct and indirect antiglobulin testing, crossmatching, and elutions. The hematocrit, serum bilirubin, clinical status, and transfusions were closely monitored. Two other confirmed cases (in Patients 5 and 7) were found on review of all ABO-unmatched liver transplantations performed at our center. Confirmed cases of isohemagglutinin production were defined as those in which passive transfer of antibody could be ruled out — i.e., either no unmatched plasma-containing blood products were given at surgery (five cases) or, if they were, immediate postoperative specimens were negative for antibody (Patients 1A, 1B, and 6) — and there was serologic or clinical confirmation of the antibody’s presence by repeat testing or signs of hemolysis. Cases were designated as possible if the antibody was first detected after the second postoperative day but the above criteria were not met in full.

Liver transplantation was performed according to established techniques, including cyclosporine immunosuppression.10,11 Little or no plasma was transferred in the grafts because the livers were copiously perfused with preservative solution and then, just before anastomosis, with saline.12 Our transfusion practices have been described elsewhere.13

RESULTS

One hundred seventy-one patients underwent a total of 225 orthotopic liver transplantations at the University of Pittsburgh from February 26, 1981, to January 20, 1984. Unmatched livers were transplanted in 40 instances (18 per cent). In 33 of these, a non-group O patient (16 group A, 15 group B, and 2 group AB patients) received a group O liver. The other seven unmatched transplants were in group AB patients who received group A (five) or group B (two) livers.

Table 1 summarizes the prevalence of anti-recipient ABO antibodies in the 40 unmatched transplants. Such antibodies were demonstrated in 8 of 29 evaluable cases (28 per cent). In addition, anti-recipient ABO antibodies were possibly present in five other transplants (17 per cent). In 13 cases no antibody was seen in specimens tested during 7 to 21 days after surgery. In three instances, antibody was detected one day after unmatched blood components had been given at surgery but all subsequent specimens were negative; these findings were attributed to the transient presence of passively acquired antibody. Eleven patients were not evaluable because of early death (four), the preoperative presence of anti-A1 in group A2 patients (two), or the absence of blood-bank specimens during the first 7 to 21 days (five).

Table 1
Prevalence of Anti-Recipient ABO Antibody in 40 Consecutive ABO-Unmatched Liver Transplants.

Table 2 shows the clinical and serologic characteristics of the eight ABO-unmatched patients in whom the presence of anti-recipient ABO antibody was confirmed. When studied with monospecific antiglobulin reagents, all patients had complement and five had IgG on their red cells. When studied with polyspecific antiglobulin reagents, freeze–thawing or heat-induced eluates from the patients’ red cells gave 1 + to 3+ reactions with other red cells of the same ABO group. In three of the transplants from group O donors, anti-A,B was present in eluates in addition to anti-A or anti-B alone in the serum. Reactions of the patients’ serum samples against appropriate red cells ranged from weak to 2+ by indirect antiglobulin testing. The reaction strength did not correlate with the degree of hemolysis. Serum samples from two patients (1A and 3) were treated with dithiothreitol to inactivate IgM; both had residual activity when tested with antiglobulin reagents, indicating the presence of IgG antibody. No other irregular red-cell antibodies were detected with group O screening cells, except for one instance of anti-Kell in serum.

Table 2
Patients in Whom Anti-Recipient ABO Antibody Was Detected.

There was evidence of hemolysis in five cases. The changes in hematocrit shown in Table 2 occurred over two to three days, well after the period of perioperative transfusion requirements (see below), and were not associated with hemorrhage. Concurrent increases in total and indirect serum bilirubin were also noted. Rejection could not be ruled out as a factor contributing to the elevation in total bilirubin levels, but it is not known to cause sudden anemia.

Figure 1 shows the period when the anti-recipient ABO antibodies were present. The antibodies were first detected 8 to 16 days after transplantation and were last detected at 11 to 41 days. Hemolysis, when it occurred, began 5 to 8 days after surgery and lasted for 7 to 19 days. In Figure 1, the final red-cell transfusion of the episode is used to indicate the end of hemolysis. In two cases complement was still present on the red cells for prolonged periods after the ABO antibody was undetectable.

Figure 1
Presence of Anti-Recipient ABO Antibodies and Hemolysis after ABO-Unmatched Liver Transplantation.

Five of these eight grafts have survived for 5 to 16 months; repeat transplants were necessary after herpesvirus and cytomegalovirus hepatitis in Patients 1A and 3 and after rejection in Patient 7. All patients except Patient 3 have survived.

DISCUSSION

In each of the eight cases reported here, circulating and red-cell-bound isohemagglutinins to the patient’s own A or B antigen were detected 8 to 16 days after transplantation of a liver from an ABO-unmatched donor. Evidence of hemolysis was present in five of the seven patients. The antibodies persisted for 2 to 4½ weeks. Passive transfer of antibody from the liver itself or from transfusions was ruled out. The findings in Patient 5, in theory, may represent hemolytic anti-A1 alloimmunization in a group A2 patient, but this is extremely rare.14

We conclude that these antibodies most probably originate from B lymphocytes that are transplanted in or with the donor liver and then respond to the recipient’s ABO antigens in a type of graft-versus-host reaction. A large number of lymphocytes may accompany the liver in the lymphatics 15,16 and lymph nodes.17 The 8-to-16-day latency period and the frequently observed IgG component of the antibodies are consistent with a secondary immune response from previously primed donor B lymphocytes. In addition, cyclosporine does not blunt secondary immune responses as much as primary ones.18,19 Proof that these antibodies are of donor origin could be obtained by immunoglobin allotyping, but in our patients this is often precluded by plasma transfusions before and at surgery.

Production of anti-recipient red-cell antibodies has also been associated with spleen,20,21 kidney,2228 and lung29 transplantation. All except one report25 involved ABO antibodies. ABO-unmatched splenic grafts have induced severe hemolysis. Patients with renal grafts, like our patients, have had short-lived, usually hemolytic antibodies appearing one to two weeks after transplantation. Designation of these antibodies as “autoantibodies”22,2429 tends to obscure their true pathogenesis.

Unless the supply of donor organs increases to allow uniform ABO matching, ABO-unmatched liver transplantation is likely to continue. To date, 20 per cent of our group A recipients, 56 per cent of our group B recipients, and 90 per cent of our group AB recipients have received ABO-unmatched livers. Our current transfusion policy in such cases is to use recipient-type blood components initially and to monitor the patients for anti-recipient ABO antibodies. If they appear, donor-type packed red cells are given when needed throughout the period when the antibody is present. During our prospective study, these red cells were washed to remove blood-donor antibodies, but the small amount of antibody in the plasma of packed red cells is unlikely to be harmful to the recipient. Plasma, if needed, should be of the recipient’s ABO type; the soluble ABO antigens therein may neutralize some of the ABO alloantibody.14

Acknowledgments

We are indebted to David Salamon for valuable discussions, to Linda Israel and the blood-bank staff for technical expertise, to Paul Chervenick, M.D., and Jessica H. Lewis, M.D., for helpful comments, and to Linda Lippert and Ruby Love for help in preparing the manuscript.

REFERENCES

1. Kashiwagi N, Groth CG, Starzl TE. Changes in serum haptoglobin and group specific component after orthotopic liver homotransplantation in humans. Proc Soc Exp Biol Med. 1968;128:247–250. [PMC free article] [PubMed]
2. Alper CA, Johnson AM, Birtch AG, Moore FD. Human C′3: evidence for the liver as the primary site of synthesis. Science. 1969;163:286–288. [PubMed]
3. Hobart MJ, Lachmann PJ, Calne RY. C6: synthesis by the liver in vivo. J Exp Med. 1977;146:629–630. [PMC free article] [PubMed]
4. Raum D, Marcus D, Alper CA, Levey R, Taylor PO, Starzl TE. Synthesis of human plasminogen by the liver. Science. 1980;208:1036–1037. [PMC free article] [PubMed]
5. Alper CA, Raum D, Awdeh ZL, Petersen BH, Taylor PD, Starzl TE. Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, α1-antitrypsin, C8, and factor B. Clin Immunol Immunopathol. 1980;16:84–89. [PubMed]
6. Miller LL, Bale WF. Synthesis of all plasma protein fractions except gamma globulins by the liver. J Exp Med. 1954;99:125–132. [PMC free article] [PubMed]
7. Kukral JC, Kerth JD, Pancner RJ, Cromer DW, Henegar GC. Plasma protein synthesis in the normal dog and after total hepatectomy. Surg Gynecol Obstet. 1961;113:360–372. [PubMed]
8. Kleinman RE, Harmatz PR, Walker WA. The liver: an integral part of the enteric mucosal immune system. Hepatology. 1982;2:379–384. [PubMed]
9. Widmann FK, editor. Technical manual of the American Association of Blood Banks. 8th ed. Philadelphia: JB Lippincott; 1981.
10. Starzl TE, Iwatsuki S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology. 1982;2:614–636. [PMC free article] [PubMed]
11. Starzl TE, Koep LJ, Halgrimson CG, et al. Fifteen years of clinical liver transplantation. Gastroenterology. 1979;77:375–388. [PMC free article] [PubMed]
12. Shaw BW, Jr, Hakala T, Rosenthal JT, Iwatsuki S, Broznick B, Starzl TE. Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet. 1982;155:321–325. [PMC free article] [PubMed]
13. Butler P, Israel L, Nusbacher J, Jenkins DE, Starzl T. Blood transfusion in liver transplantation. Transfusion. (in press) [PMC free article] [PubMed]
14. Mollison PL. Blood transfusion in clinical medicine. 7th ed. Oxford: Blackwell; 1983. pp. 291–298.
15. Parrott DMV. Lymphocyte circulation outside the lymphoid system. In: deSousa M, editor. Lymphocyte circulation: experimental and clinical aspects. New York: John Wiley; 1981. pp. 99–122.
16. Rannie GH, Donald KJ. Estimation of the migration of thoracic duct lymphocytes to non-lymphoid tissues. Cell Tissue Kinet. 1977;10:523–541. [PubMed]
17. Porter KA. Pathology of the orthotopic homograft and heterograft. In: Starzl TE, editor. Experience in hepatic transplantation. Philadelphia: WB Saunders; 1969. pp. 422–471.
18. Borel JF, Feurer C, Magnée C, Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977;32:1017–1025. [PubMed]
19. Lindsey NJ, Harris KR, Norman HB, Smith JL, Lee HA, Slapek M. The effect of cyclosporin A on the primary and secondary immune responses in the rabbit. Transplant Proc. 1980;12:252–255. [PubMed]
20. Marchioro TL, Rowlands DT, Jr, Rifkind D, Waddell WR, Starzl TE, Fudenberg H. Splenic homotransplantation. Ann NY Acad Sci. 1964;120:626–651. [PMC free article] [PubMed]
21. Salamon DJ, Ramsey G, Nusbacher J, Yang S, Starzl T, Israel L. Anti-A production by a group O spleen transplanted to a group A recipient. Vox Sang. (in press) [PMC free article] [PubMed]
22. Bird GWG, Wingham J. Anti-A autoantibodies with unusual properties in a patient on renal dialysis. Immunol Commun. 1980;9:155–159. [PubMed]
23. Stevens J, Callender CO, Jilly PN. Emergence of red blood cell agglutinins following renal transplantation in a patient with systemic lupus erythematosus. Transplantation. 1981;32:398–400. [PubMed]
24. Lundgren G, Asaba H, Bergström J, et al. Fulminating anti-A autoimmune hemolysis with anuria in a renal transplant recipient: a therapeutic role of plasma exchange. Clin Nephrol. 1981;16:211–214. [PubMed]
25. Anderson HJ, Meisenhelder J, Stevens J. Simultaneous development of auto-reactive anti-Luvar in two renal allograft recipients. Transfusion. 1983;23:436. abstract.
26. Contreras M, Hazlehurst GR, Armitage SE. Development of ‘auto-anti-A1 antibodies’ following alloimmunization in a A2 recipient. Br J Haematol. 1983;55:657–663. [PubMed]
27. Mangal AK, Growe GH, Sinclair M, Stillwell GF, Reeve CE, Naiman SC. Acquired hemolytic anemia due to “auto”-anti-A or “auto”-anti-B induced by group O homograft in renal transplant recipients. Transfusion. 1984;24:201–205. [PubMed]
28. Nyberg G, Sandberg L, Rydberg L, et al. ABO-autoimmune hemolytic anemia in a renal transplant patient treated with cyclosporine: a case report. Transplantation. 1984;37:529–530. [PubMed]
29. Bird GWG, Wingham J. Formation of blood “autoantibodies” after transplantation. Transfusion. 1982;22:400. abstract. [PubMed]